The period from September to November each year is considered the optimal time for flu vaccination. Since August, both domestic and international companies have been actively promoting influenza vaccines, with public reports indicating that the domestic vaccine market is showing strong growth. The vaccine market gap remains significant. One of the key challenges in China has been the insufficient production capacity of vaccines. Shen Xinliang, an analyst at Guojin Securities, pointed out that the domestic vaccine market is experiencing robust demand, expected to grow by approximately 15% annually. In 2007, the market size reached around RMB 3.2 billion. By 2008, the government expanded its immunization program, with the central government spending 2.5 billion yuan to purchase 14 types of vaccines. Despite this, there remains a large supply-demand gap. For instance, in 2007, the demand for the red blood cell vaccine was 63.88 million person-times, while the domestic maximum supply only reached 18 million, leaving a gap of 45.79 million person-times. "The global vaccine industry faced a downturn in the 1980s but has since rebounded with impressive momentum," said Dr. Yang Yujing, director of industrial business at GE Healthcare’s Greater China Life Sciences Department. This resurgence is driven by innovations in vaccine technology. Vaccines are no longer limited to infectious diseases—significant progress has been made in DNA vaccines, HIV vaccines, cardiovascular disease vaccines, and even cancer vaccines. Over more than 20 years since 1980, the availability of new vaccines has increased the global vaccine market by over ten times, while drug sales only grew fivefold during the same period. In response to this favorable environment, both domestic and foreign companies are making strategic moves. Novartis entered the influenza vaccine market as early as 2006. When asked about potential shortages due to a possible pandemic, Novartis China president Li Zhenfu assured that the company would prioritize supplying the Chinese market first. Similarly, French company Sanofi-Aventis has set ambitious goals for the Chinese vaccine market, planning to sell 25 million seasonal flu vaccines annually once its Shenzhen facility becomes operational in 2012. Wyeth, known for its infant formula, is also entering the vaccine space with its infant pneumococcal vaccine, marking its first product launch in China. According to Shen Qilei, Wyeth’s China vaccine market manager, the company has completed clinical trials and is currently in the registration phase. GE Healthcare also recognized the potential of the Chinese biopharmaceutical market and established the FastTrak Technology Center in Shanghai in 2006, the first downstream biotech center set up by a multinational company in China. Xia Dawei, China director of FastTrak, explained that the center supports biopharmaceutical companies with downstream purification process development and training. This technology is crucial for vaccine and biological drug production. Many Chinese vaccine companies use GE’s purification technologies, and the company’s new disposable biopharmaceutical processing products offer cost-effective and faster alternatives to traditional facilities. Xia Dawei noted that the global biopharmaceutical market has reached $6.3 billion, but China accounts for only $60 million, with the downstream purification market below $20 million. This highlights a huge opportunity for growth. With the implementation of the "Expanding National Immunization Program," vaccine companies in China are expected to see doubled market opportunities. Companies such as China Biotechnology Group, Beijing Kexing Biological Products, Beijing Tiantan Biological Products, Changchun Changsheng Biotechnology, Zhejiang Pukang Biotechnology, Zhejiang Tianyuan Biopharmaceutical, and the Institute of Medical Biology, Chinese Academy of Medical Sciences, are all poised for growth. Some, like Beijing Tiantan Biological Products, are already planning to build a new factory in Daxing, Beijing, to increase their production capacity. Currently, there are 43 vaccine manufacturers in China, producing 41 types of vaccines that protect against 26 infectious diseases, with annual output exceeding 1 billion dose units.

Aluminum Cosmetic Jars

Aluminum cosmetic containers,Aluminum cosmetic jars,packaging aluminum cans,round aluminum tin cans

Zhoushan Xinmei Packaging Products Co., Ltd , https://www.xinmeipackage.com